How Serious Is a Pancreatic Neuroendocrine Tumor?

Pancreatic neuroendocrine tumors (PNETs) are serious cancers, but they behave very differently from the pancreatic cancer most people fear. A population-based comparison found that the five-year cause-specific survival for PNETs was about 51%, compared with just 5% for pancreatic adenocarcinoma, the far more common and aggressive form of the disease.¹ That gap reflects a fundamentally different biology, but it does not mean PNETs are harmless. How serious any individual tumor is depends on its grade, whether it has spread, and whether it produces hormones that cause their own problems.

Not the Pancreatic Cancer You Have Heard About

When someone hears “pancreatic cancer,” the mind usually jumps to pancreatic ductal adenocarcinoma, which accounts for the vast majority of pancreatic malignancies and carries one of the worst prognoses of any cancer. PNETs arise from a completely different cell population: the hormone-producing endocrine cells scattered throughout the pancreas, rather than the duct-lining cells where adenocarcinomas begin. Although there has been some research suggesting the two tumor types may share certain cellular origins at the very earliest stages, clinically they remain distinct diseases with different genetics, growth speeds, and treatment landscapes.²

The practical difference is stark. In the same population-based study, a significantly larger proportion of PNETs were caught at stage I compared to adenocarcinomas (about 21% versus 6%), and a much higher share were well-differentiated, meaning the tumor cells still resemble normal tissue under a microscope. In a multivariate analysis, adenocarcinomas carried roughly four times the hazard of death compared to PNETs.¹ So while a PNET diagnosis is absolutely a serious medical event, it generally carries a far more favorable outlook than the disease people most associate with “pancreatic cancer.”

Why the Grade Matters More Than Almost Anything Else

The single biggest factor determining how aggressive a PNET will be is its grade, which reflects how quickly the tumor cells are dividing. The World Health Organization classification system separates these tumors into three tiers. Grade 1 tumors have the slowest growth rate, grade 2 tumors are intermediate, and grade 3 tumors are the fastest-dividing and most dangerous.³ Two measurements drive the grading: how many dividing cells a pathologist counts under the microscope (the mitotic rate) and the Ki-67 index, which measures the fraction of tumor cells actively preparing to divide.

Grading is not always straightforward. A study of 264 tumors that were classified as grade 1 by mitotic count found that a third of them actually qualified as grade 2 when Ki-67 was factored in. Those “discordant” tumors behaved more aggressively: they were more likely to have spread to lymph nodes (56% versus 34%) and to distant sites (46% versus 12%), and median survival was roughly 12 years compared to nearly 17 years for tumors that were consistently grade 1 by both measures.⁴ The takeaway for patients is that a grade 1 label on a pathology report is not automatically reassuring unless both markers agree.

At the other end of the spectrum, grade 3 tumors are themselves a mixed bag. Some are well-differentiated tumors that happen to divide quickly, while others are poorly differentiated neuroendocrine carcinomas with very different biology. This distinction matters because the well-differentiated G3 tumors tend to respond better to certain treatments. In one study, capecitabine and temozolomide chemotherapy achieved a disease control rate of 87% in well-differentiated G3 tumors but only about 43% in poorly differentiated ones.⁵

Functional Versus Non-Functional Tumors

PNETs split into two broad categories based on whether they produce excess hormones. Functional tumors secrete hormones that cause recognizable clinical syndromes. The most common of these are insulinomas, which flood the bloodstream with insulin and cause dangerously low blood sugar, and gastrinomas, which overproduce gastrin and trigger severe stomach ulcers. Rarer functional types include glucagonomas, VIPomas, and tumors that secrete ACTH or other hormones.⁶ Functional tumors often get caught earlier precisely because the hormonal symptoms bring patients to a doctor before the tumor has had time to grow large or spread.

Non-functional tumors, which make up the majority of PNETs, do not produce hormones that cause symptoms. They tend to grow silently for years and are frequently discovered incidentally during imaging for something else, or only when they grow large enough to press on nearby structures or spread to the liver. While most non-functional PNETs are slow-growing, the higher-grade ones can become incurable once they reach unresectable metastatic disease.⁷ Certain imaging features, such as calcifications and reduced enhancement on CT, can help doctors suspect a higher-grade tumor before surgery.

When PNETs Run in Families

About 10% of PNETs occur as part of an inherited genetic syndrome rather than arising spontaneously. The best known is multiple endocrine neoplasia type 1 (MEN1), a condition caused by mutations in the MEN1 gene, which normally produces a tumor-suppressor protein called menin. When both copies of the gene lose function in pancreatic endocrine cells, tumors can develop.⁸ Other inherited conditions linked to PNETs include von Hippel-Lindau disease, neurofibromatosis type 1, tuberous sclerosis complex, and the more recently identified MEN4 syndrome.⁹

Knowing whether a PNET is syndromic changes management in important ways. People with MEN1, for example, often develop multiple small tumors throughout the pancreas rather than a single mass, and they need lifelong surveillance for tumors in other organs as well, particularly the parathyroid glands and pituitary. There is also evidence that patients with germline mutations may respond differently to targeted drugs. In one study comparing everolimus treatment in sporadic versus hereditary PNETs, patients with germline mutations achieved numerically better disease control rates (about 88% versus 68%) and longer progression-free survival, although the study was too small to reach statistical significance.¹⁰

Surgery and the Question of Recurrence

For PNETs that have not spread widely, surgery is the primary treatment and the only realistic shot at a cure. Depending on the tumor’s location, the operation might involve removing the tail of the pancreas, the head (a more complex procedure called a pancreatoduodenectomy), or simply shelling the tumor out of the pancreas in a procedure called enucleation.¹¹ In a large surgical series, the five- and ten-year disease-free survival rates after resection were about 86% and 81%, respectively.¹²

Recurrence remains a real concern, however, and the liver is overwhelmingly where it shows up. Among patients with well-differentiated G1 or G2 tumors who underwent upfront surgery, about a quarter experienced a recurrence, with the liver accounting for 77% of those cases. The average time to recurrence was nearly five years, and the only factor independently associated with a higher risk was the presence of cancer in the lymph nodes at the time of the original operation.¹³ That long lead time before relapse means surveillance needs to continue for years, well beyond what many patients expect.

Treatments for Advanced or Metastatic Disease

When PNETs spread beyond the reach of a surgeon’s knife, the treatment strategy shifts to controlling growth and managing symptoms. Several classes of therapy have proven effective, and they can often be used in sequence over many years.

Somatostatin analogs like lanreotide and octreotide are often a first step for well-differentiated tumors with low-to-moderate growth rates. A major trial showed that lanreotide roughly doubled the proportion of patients alive without disease progression at two years compared to placebo (about 65% versus 33%), with a hazard ratio of 0.47 for progression or death.¹⁴ These drugs work partly by mimicking a natural hormone that slows the release of other hormones, and partly by directly inhibiting tumor cell growth. Side effects tend to be manageable, most commonly digestive complaints.

When tumors progress on somatostatin analogs, targeted drugs are the next line of defense. Everolimus, which blocks a growth-signaling pathway called mTOR, extended median progression-free survival to 11 months compared to about 4.6 months for placebo in a landmark trial, representing a 65% reduction in the risk of progression or death.¹⁵ Sunitinib, which targets blood vessel growth, has shown similar efficacy. Importantly, when one targeted drug stops working, switching to the other can still provide benefit; studies have found that the total progression-free survival achieved by using both drugs sequentially is comparable regardless of which one comes first, at roughly 32 to 37 months combined.¹⁶

Peptide Receptor Radionuclide Therapy

One of the more innovative treatments available for PNETs is peptide receptor radionuclide therapy, often called PRRT. This approach attaches a radioactive molecule to a peptide that binds to receptors found on the surface of most well-differentiated neuroendocrine tumor cells, delivering targeted radiation directly to the cancer while largely sparing normal tissue. Data from prospective and retrospective studies show median progression-free survival ranging from 20 to 39 months and median overall survival from 37 to 79 months, depending on the patient population.¹⁷

Tracking response to PRRT can be tricky because tumor shrinkage sometimes lags behind functional changes. One study found that tumor growth rate shifted from an average of 6% per month before treatment to negative values (meaning tumors were actively shrinking) within the first few months of therapy. Patients whose tumors continued growing at a rate above 0.5% per month after treatment had significantly shorter progression-free survival (about 16 months versus nearly 32 months), suggesting that early growth-rate assessments could help identify who is benefiting and who might need a different approach.¹⁸

When Liver Metastases Are Already Present

Because the liver is the most common site of PNET spread, the management of liver metastases deserves particular attention.¹⁹ When feasible, surgical removal of liver metastases is thought to offer the best long-term results. But many patients have disease too widespread for surgery, and for them, several liver-directed therapies exist. These include procedures that cut off the blood supply to tumors within the liver (embolization), combine that blood-supply blockade with chemotherapy drugs delivered directly to the tumor (chemoembolization), or use tiny radioactive beads injected into the liver’s arterial blood supply (radioembolization). These approaches can slow disease progression, ease symptoms, and buy time for systemic therapies to work.²⁰

Finding PNETs and Tracking Them Over Time

Detection has improved considerably with specialized imaging. A study comparing gallium-68 DOTATATE PET/CT (which targets the somatostatin receptors that most well-differentiated PNETs express) to abdominal MRI found that PET/CT detected 100% of pancreatic neuroendocrine tumors in both observers, significantly outperforming MRI.²¹ This scan has become central not just for diagnosis but for determining eligibility for PRRT, since tumors need to light up on the scan to be good candidates for the therapy.

Beyond imaging, blood-based tests are evolving. A multigene liquid biopsy called the NETest measures the expression of 51 genes specific to neuroendocrine tumors. In validation studies, it achieved about 97% accuracy for distinguishing neuroendocrine tumors from healthy controls and was over 90% concordant with imaging results.⁶ An updated version using machine learning showed sensitivity above 90% for detecting both disease presence and disease progression.²² For post-surgical monitoring, this blood test has shown promise in catching recurrences that the traditional marker chromogranin A misses entirely: in one study, the NETest correlated with recurrence with an area under the curve of 0.82, while chromogranin A performed barely better than a coin flip at 0.51.²³

Why Immunotherapy Has Not Changed the Game for PNETs

Given how much attention immunotherapy receives in oncology, patients often ask whether checkpoint inhibitors like those used in melanoma and lung cancer are an option. For well-differentiated PNETs, the answer is largely no, at least for now. These tumors tend to have low levels of PD-L1 expression, they are generally proficient at DNA mismatch repair, and their overall tumor mutational burden is low. All three factors are associated with poor response to immune checkpoint blockade.²⁴ Poorly differentiated neuroendocrine carcinomas, which sit at the opposite end of the spectrum with higher mutational burdens, are considered better candidates, but research in that space is still in relatively early stages.

Life After Treatment

Because many PNET patients live for years or decades, quality of life after treatment is not an afterthought. A study of 100 patients surveyed more than a decade after surgery found that overall quality of life was good, with a median score of about 83 out of 100. The biggest drags on quality of life were diabetes (which can result from losing pancreatic tissue during surgery), older age, and multiple other health conditions. Patients who had undergone tissue-sparing surgical approaches reported less fatigue than those who had more extensive operations.²⁵

Financial strain is an underappreciated dimension of living with a PNET. In one study, 57% of patients reported that their financial stability had been affected by the disease, and more than a quarter had to quit their jobs after diagnosis.²⁶ An Australian survey found that poorer quality of life was significantly associated with higher financial toxicity, along with not being able to work because of the cancer, persistent nausea or diarrhea, and having two or more other health problems.²⁷ The long timeline of PNETs, which often involve years of periodic scans, specialist visits, and costly medications, compounds this burden in ways that faster-moving cancers sometimes do not. For many patients, addressing financial toxicity proactively is as important as selecting the right drug.

1
American Journal of Clinical Oncology. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study
2
PubMed Central. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma
3
PubMed Central. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms
4
PubMed Central. Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate
5
ESMO Open. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
6
PubMed Central. NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging
7
PubMed Central. Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management
8
PubMed Central. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1
9
PubMed Central. Inherited syndromes involving pancreatic neuroendocrine tumors
10
PubMed Central. The efficacy of everolimus and sunitinib in patients with sporadic or germline mutated metastatic pancreatic neuroendocrine tumors
11
Surgery, Gastroenterology and Oncology. Pancreatic Neuroendocrine Tumors – Analysis of Recurrence after Surgical Resection and its Effect on Overall Survival
12
PubMed Central. Time-trend and recurrence analysis of pancreatic neuroendocrine tumors
13
PubMed Central. Recurrence and treatment trends of pancreatic neuroendocrine tumors
14
PubMed. Lanreotide in metastatic enteropancreatic neuroendocrine tumors
15
PubMed Central. Everolimus for advanced pancreatic neuroendocrine tumors
16
Neuroendocrinology. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments
17
PubMed Central. Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights
18
PubMed Central. Tumor growth rate in pancreatic neuroendocrine tumor patients undergoing PRRT with 177Lu-DOTATATE
19
PubMed Central. Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: a multicenter study
20
PubMed Central. Surgical management of pancreatic neuroendocrine liver metastases
21
PubMed. Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas
22
PubMed Central. NETest® 2.0-A decade of innovation in neuroendocrine tumor diagnostics
23
PubMed. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors
24
PubMed Central. Characterization of the Pancreatic Neuroendocrine Neoplasm Immune Microenvironment
25
PubMed Central. Quality of Life After Pancreatic Surgery for Neuroendocrine Tumors of the Pancreas: Observational Study of Long-Term Outcomes
26
Endocrine Abstracts. Financial Toxicity and Supportive Care in Neuroendocrine Tumor: A Biobank Study
27
PubMed. The Economic Impact on Australian Patients with Neuroendocrine Tumours